© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
April 04, 2022
Closing out their discussion on graft-versus-host disease, participants reflect on patient prognoses and the future directions of care.
A brief discussion on the risk of treatment-induced damage when managing patients with chronic graft-versus-host disease.
Having reviewed approved treatment options for steroid-refractory, chronic GVHD, experts discuss how they would address this patient scenario.
Considerations for belumosudil and axatilimab as treatment options for steroid-refractory chronic graft-versus-host disease.
A review of treatment options approved for steroid-refractory chronic graft-versus-host disease starting with ibrutinib and ruxolitinib.
Shared insight on how to distinguish chronic GVHD from acute GVHD, as well as utilize appropriate methods to risk stratify disease.